[Asia Economy Reporter Hyungsoo Park] NKMAX is showing strong performance. It appears that the news of Professor Kyungmi Lee's research team at Korea University College of Medicine initiating emergency clinical trials of NKMAX's ‘SuperNK’ immune cell therapy for COVID-19 has influenced the stock price.
As of 10:10 AM on the 26th, NKMAX is trading at 8,200 KRW, up 7.19% from the previous day.
SuperNK is an immune cell therapy based on NK cells developed by NKMAX. It is a drug that maximizes the attack power against viruses and abnormal cells. Professor Kyungmi Lee stated, "In a recent Chinese research paper conducted on COVID-19 infected patients, NK cells were found to be significantly reduced compared to healthy individuals," and added, "We confirmed that the expression of the receptor (NKG2A) that suppresses NK cell activity was elevated."
She continued, "According to the research paper, it is important to prevent immune cell deficiency and improve NK cell immune response in the early stages of infection," emphasizing, "If the patient's NK cell activity is increased, meaningful therapeutic effects are expected."
Professor Lee said, "SuperNK, which has confirmed the necessary safety in emergency clinical trials, is judged to be the optimal drug, and we are preparing for this clinical trial."
Kim Yongman, head of research at NKMAX, said, "SuperNK is expected to yield effective results in treating various viruses, including COVID-19." He added, "If the Korea University College of Medicine research team confirms the therapeutic effect of COVID-19 through emergency clinical trials, it will secure a pipeline extending beyond cancer treatment to viral therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
